New Orleans—Statin therapy using 80 mg of simvastatin daily may be on its last legs, some physicians suggest, because the drug is associated with increased risk of myopathy. In addition, when compared with the drug's efficacy at lower doses, high-dose simvastatin is minimally or no more effective in reducing low-density lipoprotein cholesterol (LDL-C) or decreasing risk of major vascular events.
The negative appraisal of high-dose simvastatin was prompted by new results from the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH), presented at the Scientific Sessions of the American Heart Association held here in November.
Mitka M. Researchers Worry About Myopathy Risk for Patients Taking High-Dose Simvastatin. JAMA. 2009;301(3):261–262. doi:https://doi.org/10.1001/jama.2008.939
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: